Goldman Sachs analyst David Roman maintained a Hold rating on Kestra Medical Technologies Ltd. today and set a price target of $20.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
David Roman has given his Hold rating due to a combination of factors surrounding Kestra Medical Technologies Ltd.’s recent performance and future outlook. The company’s 4QFY25 revenue showed a significant year-over-year increase and exceeded expectations, driven by a rise in prescriptions and improved revenue cycle management. However, despite these positive developments, the company reported a larger-than-expected EBITDA loss, indicating higher investments in its commercial strategy.
Furthermore, while Kestra’s guidance for FY2026 suggests continued revenue growth, the market environment remains challenging with moderate growth expectations. The company’s gross margins have improved, yet the overall financial returns and market conditions warrant a cautious approach. Therefore, considering these mixed signals, David Roman has opted for a Hold rating, reflecting a balanced view of potential risks and opportunities.